what is in retatrutide Dosing Explained: You Need To Know Retatrutide Significantly Reduces Visceral Fat

Among the participants, 1,320 had pre-diabetes at the start of the study, defined by blood sugar levels between 5.7%-6.4%

The large 2025 meta-analysis quantified this as approximately 63% higher gastrointestinal adverse event rates compared with placebo, and gallbladder disorders were about 26% higher

This leads to slower absorption of glucose and other macronutrients, preventing rapid blood sugar spikes

The human bias toward immediate comfort over distant benefit often prevails

Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors, with phase 2 data published in the New England Journal of Medicine (2023) showing substantial weight reduction